Showing results (311-320 of 724) with videos related to

Sort By:
Pageof 73
Clinicoeconomics and Outcomes Research : CEOR|September 15, 2018
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilarLee S Schwartzberg, Lincy S Lal, Sanjeev Balu, et al.
Current Medical Research and Opinion|February 12, 2011
Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC)Lee Schwartzberg, Stephen Szabo, James Gilmore, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|June 21, 2005
Accuracy and predictors of basal cell carcinoma diagnosisJordan B Schwartzberg, George W Elgart, Paolo Romanelli, et al.
Small (Weinheim an Der Bergstrasse, Germany)|April 23, 2013
Triggering and monitoring plasmon-enhanced reactions by optical nanoantennas coupled to photocatalytic beadsMarco Salmistraro, Adam Schwartzberg, Wei Bao, et al.
Molecular Cell|January 15, 2000
Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeabilityB P Eliceiri, R Paul, P L Schwartzberg, et al.
Springerplus|September 29, 2015
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studiesJoyce O'Shaughnessy, Kristi McIntyre, Lee Schwartzberg, et al.
Clinical Lung Cancer|May 28, 2019
Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum ChemotherapyLee Schwartzberg, Beata Korytowsky, John R Penrod, et al.
BMC Cancer|June 15, 2019
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancerLee Schwartzberg, Kristi McIntyre, Sharon Wilks, et al.
The Oncologist|November 25, 2004
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancerLee S Schwartzberg, Lorrin K Yee, Frank M Senecal, et al.
The Oncologist|February 17, 2010
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancerLee S Schwartzberg, Lee S Schwarzberg, Sandra X Franco, et al.
Pageof 73